Tyrosine kinase inhibitors therapy related neutropenia and thrombocythopenia correction in CML patients

Abstract

At present, introduction of target therapy to chronic myelogenous leukemia (CML) treatment made CML not life-limiting disorder. The main condition of treatment efficacy is its continuity. The most common causes of dose reduction and CML therapy interruption is hematologic toxicities such as neutropenia and thrombocytopenia. The adverse events correction in these circumstances is vital. Recommendations for neutropenia and thrombocytopenia correction are proposed in this article. The basement and results of the use of granulocyte colony stimulating factor (G-CSF) and thrombopoietine receptor agonist for hematologic toxicities correction with clinical case are presented.

Keywords

• chronic myelogenous leukemia
• tyrosine kinase inhibitors
• imatinib
• dasatinib
• thrombocythopenia
• neutropenia
• romiplostim